,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': 'This is a PHARMAC-initiated application following advice from the Cystic Fibrosis Panel.', 'fs': 'This is a PHARMAC-initiated application following advice from the Cystic Fibrosis Panel.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3eUAG'}, 'Id': 'a0P2P000005PA3eUAG', 'Event_Date__c': '2014-05-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'This is a PHARMAC-initiated application following advice from the Cystic Fibrosis Panel.', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqeNQAS'}, 'change': None}]",May 2014,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Subcommittee recommend that dornase alfa be made available to all cystic fibrosis patients under the age of 6 years, with the proviso that the Cystic Fibrosis Panel consider an appropriate objective measure to identify patients who respond to treatment.', 'fs': 'The Subcommittee recommend that dornase alfa be made available to all cystic fibrosis patients under the age of 6 years, with the proviso that the Cystic Fibrosis Panel consider an appropriate objective measure to identify patients who respond to treatment.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2015-03.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2015-03.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2015', 'fs': 'Mar 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 4 March 2015.', 'fs': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 4 March 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3gUAG'}, 'Id': 'a0P2P000005PA3gUAG', 'Event_Date__c': '2015-03-04', 'Event_Description__c': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 4 March 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2015-03.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Summary__c': 'The Subcommittee recommend that dornase alfa be made available to all cystic fibrosis patients under the age of 6 years, with the proviso that the Cystic Fibrosis Panel consider an appropriate objective measure to identify patients who respond to treatment.', 'Formatted_Date__c': 'Mar 2015', 'Status_History__c': 'a132P000000AqseQAC'}, 'change': None}, {'Summary': {'s': 'The Committee asked to see the evidence and costs associated with widening access to treatment to all cystic fibrosis patients under the age of 6 years old and requested the Respiratory Subcommittee develop criteria for access to dornase alfa for this age group.  The Committee asked for this information to be presented at its November 2015 meeting.', 'fs': 'The Committee asked to see the evidence and costs associated with widening access to treatment to all cystic fibrosis patients under the age of 6 years old and requested the Respiratory Subcommittee develop criteria for access to dornase alfa for this age group.  The Committee asked for this information to be presented at its November 2015 meeting.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2015', 'fs': 'Aug 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3jUAG'}, 'Id': 'a0P2P000005PA3jUAG', 'Event_Date__c': '2015-08-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Committee asked to see the evidence and costs associated with widening access to treatment to all cystic fibrosis patients under the age of 6 years old and requested the Respiratory Subcommittee develop criteria for access to dornase alfa for this age group.  The Committee asked for this information to be presented at its November 2015 meeting.', 'Formatted_Date__c': 'Aug 2015', 'Status_History__c': 'a132P000000AqxzQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3kUAG'}, 'Id': 'a0P2P000005PA3kUAG', 'Event_Date__c': '2016-02-11', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar4iQAC'}, 'change': None}, {'Summary': {'s': 'Recommended widening access to children under 5, subject to restrictions as listed in the minutes.', 'fs': 'Recommended widening access to children under 5, subject to restrictions as listed in the minutes.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3lUAG'}, 'Id': 'a0P2P000005PA3lUAG', 'Event_Date__c': '2016-02-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 February 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-02-update.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Medium', 'Summary__c': 'Recommended widening access to children under 5, subject to restrictions as listed in the minutes.', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar4mQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""http://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2017-08.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'fs': '<a href=""http://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2017-08.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2017', 'fs': 'Aug 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 4 August 2017.', 'fs': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 4 August 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3rUAG'}, 'Id': 'a0P2P000005PA3rUAG', 'Event_Date__c': '2017-08-04', 'Event_Description__c': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 4 August 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""http://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2017-08.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Aug 2017', 'Status_History__c': 'a132P000000ArJVQA0'}, 'change': None}]",Mar 2015,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2015', 'fs': 'Mar 2015', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3fUAG'}, 'Id': 'a0P2P000005PA3fUAG', 'Event_Date__c': '2015-03-04', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2015', 'Status_History__c': 'a132P000000AqsaQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3mUAG'}, 'Id': 'a0P2P000005PA3mUAG', 'Event_Date__c': '2016-02-12', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar5DQAS'}, 'change': None}]",Mar 2015,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2016', 'fs': 'Jun 2016', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3nUAG'}, 'Id': 'a0P2P000005PA3nUAG', 'Event_Date__c': '2016-06-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2016', 'Status_History__c': 'a132P000000Ar9RQAS'}, 'change': None}]",Jun 2016,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2015', 'fs': 'Mar 2015', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3hUAG'}, 'Id': 'a0P2P000005PA3hUAG', 'Event_Date__c': '2015-03-09', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Mar 2015', 'Status_History__c': 'a132P000000AqsoQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2016', 'fs': 'Oct 2016', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3oUAG'}, 'Id': 'a0P2P000005PA3oUAG', 'Event_Date__c': '2016-10-11', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Oct 2016', 'Status_History__c': 'a132P000000ArCSQA0'}, 'change': None}]",Mar 2015,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': 'Consults on changes to several pharmaceuticals. Includes a proposal to amend access to dornase alfa, to allow access to patients under the age of six, and also to remove the FEV1 requirement from the eligibility criteria for long term use of dornase alfa.', 'fs': 'Consults on changes to several pharmaceuticals. Includes a proposal to amend access to dornase alfa, to allow access to patients under the age of six, and also to remove the FEV1 requirement from the eligibility criteria for long term use of dornase alfa.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/news/consultation-2015-03-09-various-pharmaceuticals/"" target=""_blank"">Consultation letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/news/consultation-2015-03-09-various-pharmaceuticals/"" target=""_blank"">Consultation letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2015', 'fs': 'Mar 2015', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3iUAG'}, 'Id': 'a0P2P000005PA3iUAG', 'Event_Date__c': '2015-03-23', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<a href=""https://www.pharmac.govt.nz/news/consultation-2015-03-09-various-pharmaceuticals/"" target=""_blank"">Consultation letter</a>', 'Summary__c': 'Consults on changes to several pharmaceuticals. Includes a proposal to amend access to dornase alfa, to allow access to patients under the age of six, and also to remove the FEV1 requirement from the eligibility criteria for long term use of dornase alfa.', 'Formatted_Date__c': 'Mar 2015', 'Status_History__c': 'a132P000000AqtGQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/news/consultation-2016-10-11-multi-product-proposal/"" target=""_blank"">Consultation letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/news/consultation-2016-10-11-multi-product-proposal/"" target=""_blank"">Consultation letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3pUAG'}, 'Id': 'a0P2P000005PA3pUAG', 'Event_Date__c': '2016-11-08', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<a href=""https://www.pharmac.govt.nz/news/consultation-2016-10-11-multi-product-proposal/"" target=""_blank"">Consultation letter</a>', 'Formatted_Date__c': 'Nov 2016', 'Status_History__c': 'a132P000000ArDlQAK'}, 'change': None}]",Mar 2015,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/news/notification-2016-12-05-multi-product-proposal/"" target=""_blank"">Notification letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/news/notification-2016-12-05-multi-product-proposal/"" target=""_blank"">Notification letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2016', 'fs': 'Dec 2016', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005PA3qUAG'}, 'Id': 'a0P2P000005PA3qUAG', 'Event_Date__c': '2016-12-02', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<a href=""https://www.pharmac.govt.nz/news/notification-2016-12-05-multi-product-proposal/"" target=""_blank"">Notification letter</a>', 'Formatted_Date__c': 'Dec 2016', 'Status_History__c': 'a132P000000ArElQAK'}, 'change': None}]",Dec 2016,False,True
